Proanthocyanidins are a class of polyphenolic that are widely distributed in higherplants, consisted of an electrophilic flavanyl unit. Proanthocyanidins can be used as antioxidant and anti-cancers agent. Proanthocyanidins also exhibit anti-inflammatory, cardioprotective, antibacterial and antifungal properties, which can be used in the treatment of chronic venous insufficiency, capillary fragility, sunburn and retinopathy.^[1].

Proanthocyanidins are present in plants as complex mixtures of polymers. Predominant food sources are red wine, tea, chocolate and fruits like grapes, apples, pears, and cranberries^[1].
The most interesting antibacterial activity of Proanthocyanidins is related to their presence in cranberries (Vaccinium macrocarponAit.). A number of clinical trials have demonstrated the effectiveness of cranberry consumption in preventing urinary tract infections (UTIs). Although UTIs can be caused by many microorganisms, more than 85% are caused by Escherichia coli. The presence of P-fimbriae onE. coli, which are proteinaceous fibers on the bacterial cell wall, has been clearly established as a virulence factor, since they are responsible by producing adhesions for adherence to uroepithelial cells. Recently, it is demonstrated that cranberry Proanthocyanidins might inhibit P-fimbriatedE. colifrom adhering to uroepithelial cells. The antiadhesion activity of cranberry juice appears to be related to the presence of Proanthocyanidins with at least one A-type linkage^[1].

The effects of cacao liquor Proanthocyanidins on 2- amino-1-methyl-6-phenylimidazo [4,5-b] pyridine-induced mutagenesis in vivo carcinogenesis in female Sprague-Dawley rats are investigated. In the Ames assay, Proanthocyanidins shows strong antimutagenic effects when assayed in the presence of S-9 mixture. They also inhibit significantly rat pancreatic carcinogenesis in the initiation stage, but not mammary carcinogenesis^[1].

594.52

Solid

C₃₀H₂₆O₁₃

20347-71-1

原花青素

• Flavonoids
• Biflavones

• Phenols
• Polyphenols

• Plants
• other families

Room temperature in continental US; may vary elsewhere.

DMSO : 100 mg/mL(168.20 mM;Need ultrasonic)

H₂O : 5 mg/mL(8.41 mM;ultrasonic and adjust pH to 11 with Na2CO3)

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂： 10% DMSO    40%PEG300   5%Tween-80   45% saline

  Solubility: 2.5 mg/mL (4.21 mM); Suspended solution; Need ultrasonic

  此方案可获得 2.5 mg/mL (4.21 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

  以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

  将 0.9 g 氯化钠，完全溶解于 100 mL ddH2O 中，得到澄清透明的生理盐水溶液
• 2.

  请依序添加每种溶剂： 10% DMSO    90% (20%SBE-β-CDin saline)

  Solubility: ≥ 2.5 mg/mL (4.21 mM); Clear solution

  此方案可获得 ≥ 2.5 mg/mL (4.21 mM，饱和度未知) 的澄清溶液。

  以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

  将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明